Update on Advanced Gastric Cancer: Guidelines and Current and Emerging Targeted Therapies

September 10, 2014

This activity is supported by an educational grant from Eli Lilly.

Charles S. Fuchs, MD, MPH

Director of the Gastrointestinal Malignancy Program

Dana-Farber Cancer Institute

Boston, Massachusetts

Faculty Reviewer

Jaffer A. Ajani, MD

Professor of Cancer Medicine

MD Anderson Cancer Center

The University of Texas

Houston, Texas

Editorial Support

Paige S. Davies, PhD

Katherine DeYoung, PhD

Hitt Medical Writing, LLC

This activity is supported by an educational grant from Eli Lilly.

Activity Overview

This activity is designed to educate oncologists, surgical oncologists, gastroenterologists, pathologists, and oncology nurses on the optimal management of advanced gastric cancer.

It includes background on gastric cancer and information on the underlying signaling pathways in advanced gastric cancer, including human epidermal growth factor receptors, vascular endothelial growth factor receptors, and the MET hepatocyte growth factor receptor. This CME activity also includes the most recent clinical practice guidelines for management of gastric cancer as well as information on HER2 status and trastuzumab clinical trial data. This CME includes late-stage clinical trial data on emerging targeted therapies for the treatment of advanced gastric cancer, including ramucirumab, apatinib, neratinib, lapatinib, trastuzumab emtansine (T-DM1), pertuzumab, rilotumumab, and onartuzumab. Lastly, this CME introduces readers to immune-based therapies in gastric cancer.

Educational Objectives

  • Summarize aberrant signaling pathways in advanced gastric cancer
  • Develop treatment regimens for patients with gastric cancer based on recently updated guidelines
  • Analyze recent clinical trial data on emerging targeted therapies for the treatment of advanced gastric cancer

Upon completion of this educational activity, participants should be able to:Target Audience:Oncologists, surgical oncologists, gastroenterologists, pathologists, and oncology nurses

Type of Activity:Knowledge

Release date:August 30, 2014

Expiration date:August 30, 2015

Estimated time to complete activity:2 hours

To continue, click here > >